Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Imaging Studies V: Intravenous Urography and Retrograde Pyelography

Imaging Studies V: Intravenous Urography and Retrograde Pyelography

IntroductionIntravenous Urography (IVU) and Retrograde Pyelography (RP) are important diagnostic imaging techniques used to evaluate the urinary system. These methods help identify structural abnormalities, obstructions, and functional issues in the kidneys, ureters, and bladder. Both procedures use iodine-based contrast media to enhance the visibility of urinary tract structures on X-ray images, though they differ in their methods and indications.1. Intravenous Urography (IVU)Intravenous...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Importance of Protocol Standards in the Preparation of Breast Sentinel Node Injections.

Journal of nuclear medicine technology·2026

Same author

Simulation-Enhanced Learning in Nuclear Medicine: Theory, Modalities, and Applications Across the Training Continuum.

Journal of nuclear medicine technology·2026

Same author

Simulation-Enhanced Learning in Nuclear Medicine: Practical-Use SCAFFOLD.

Journal of nuclear medicine technology·2026

Same author

Prostate Cancer: Staging, Progression, and Treatment.

Journal of nuclear medicine technology·2026

Same author

Impact of <sup>18</sup>F-FDG Vials on Well Counter Background Radiation: Evaluating Shielding and Distance Effects.

Journal of nuclear medicine technology·2025

Same author

Role and Qualifications of Nuclear Medicine Technologists on the Theranostic Team.

Journal of nuclear medicine technology·2025

Same journal

<sup>18</sup>F-NaF PET/CT Versus <sup>18</sup>F-FDG PET/CT for Baseline Mapping in Ollier Disease: A Pediatric Case.

Journal of nuclear medicine technology·2026

Same journal

Incidental Detection of Aggressive HER2-Positive Breast Cancer on <sup>99m</sup>Tc-Sestamibi Parathyroid Scintigraphy.

Journal of nuclear medicine technology·2026

Same journal

Structured Educational Tours in Hospital-Based Radiopharmaceutical Production: Balancing Safety and Learning.

Journal of nuclear medicine technology·2026

Same journal

Development of a Phantom for Evaluating Image Quality and Partial-Volume Effects in Hot and Cold Regions in Small-Animal SPECT and PET.

Journal of nuclear medicine technology·2026

Same journal

Nonuniformity in a Certified <sup>68</sup>Ge PET Cylinder Phantom: Implications for Normalization Quality Assurance.

Journal of nuclear medicine technology·2026

Same journal

Reducing Formation of Suspected Tracer Microemboli During Preparation of <sup>99m</sup>Tc-Tagged Heat-Damaged Red Blood Cells.

Journal of nuclear medicine technology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 12, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Prostate Cancer Imaging with ¹⁸F-Flotufolastat.

David Gilmore¹, Daniel Tempesta²

¹Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts; and david.gilmore@mcphs.edu.

Journal of Nuclear Medicine Technology

|November 4, 2025

Summary

This summary is machine-generated.

¹⁸F-flotufolastat (Posluma) improves detection of metastatic prostate cancer by targeting prostate-specific membrane antigen (PSMA)-positive lesions. Its favorable pharmacokinetics enhance visualization, aiding in accurate staging and treatment planning.

Keywords:

18F-flotufolastat PSMA clinical trials metastases prostate cancer prostate-specific membrane antigen

More Related Videos

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

Published on: January 11, 2020

Related Experiment Videos

Last Updated: Jan 12, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

Published on: January 11, 2020

Area of Science:

Nuclear Medicine
Oncology
Radiopharmaceutical Development

Background:

Prostate cancer metastasis detection is crucial for patient survival rates.
Nuclear medicine and PSMA-targeted agents have advanced prostate cancer imaging.
Challenges remain in visualizing pelvic lesions due to factors like bladder activity.

Purpose of the Study:

To evaluate the role of ¹⁸F-flotufolastat (Posluma) in detecting PSMA-positive prostate cancer lesions.
To highlight the diagnostic accuracy and safety of ¹⁸F-flotufolastat in clinical trials.
To discuss the logistical and clinical advantages of ¹⁸F-flotufolastat in prostate cancer management.

Main Methods:

Utilized ¹⁸F-flotufolastat, a novel PSMA-targeted PET radiopharmaceutical.
Conducted clinical trials (e.g., LIGHTHOUSE, SPOTLIGHT) to assess diagnostic performance.
Analyzed pharmacokinetic properties, including urinary excretion and bladder activity.

Main Results:

¹⁸F-flotufolastat demonstrated high specificity and diagnostic accuracy in identifying PSMA-positive lesions.
Favorable pharmacokinetics, including low urinary excretion, improved lesion detectability, especially in the pelvic region.
Clinical trials confirmed a good safety profile across various patient groups.

Conclusions:

¹⁸F-flotufolastat (Posluma) is a significant advancement in nuclear medicine for prostate cancer imaging.
Its ability to precisely visualize metastatic sites offers valuable insights for treatment decisions.
The agent's characteristics provide logistical benefits for healthcare facilities and flexibility for patient scans.